Clinical Trial Update: SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of SJG-136 in relapsed or refractory hematologic cancers (acute myeloid leukemia subtypes, myelodysplastic syndromes, blast-phase chronic myelogen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Myelodysplastic Syndromes
• Myelogenous Leukemia
• Myelogenous Leukemia Blast Crisis

Drugs mentioned

• SJG-136

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Status: TERMINATED